


## Regioselective synthesis of 2-(1*H*-benzimidazol-1-yl)-5-nitro- and 2-(5-nitro-1*H*-benzimidazol-1-yl)anilines

Roman S. Begunov, Anna V. Chetvertakova and Margarita E. Neganova

### Table of contents

1. Experimental Procedures and Analytical Data.....	S1-S4
2. NMR Spectral Data.....	S5-S19



Scheme S1

### 1. Experimental Procedures and Analytical Data

The melting points were determined with a Poly Therm A instrument with a heating rate of 3 °C and were not corrected. NMR spectra were recorded at the N.D. Zelinsky Institute of Organic Chemistry of the Russian Academy of Sciences.  $^1H$  NMR spectra were recorded on a Bruker DRX500 instrument at a frequency of 500 MHz  $^{13}C$  NMR spectra were recorded at a frequency of 125 MHz using DMSO- $d_6$  as the solvent and internal standard. High-resolution mass spectra were recorded on a Bruker micrOTOF II instrument (Bruker Daltonics) with the electrospray ionization method (ESI) and MeCN as the solvent.

**Method for the synthesis of *N*-(2-chloro-5-nitrophenyl)propanamide (4a) and *N*-(4-chloro-3-nitrophenyl)propanamide (4b).** A solution of nitroaniline **3a** or **3b** (5 g, 29 mmol) in DMF (20 ml) and propionic anhydride (5.6 g, 43 mmol) was heated at 90 °C for 1 h. After cooling, the reaction mixture was poured into water. The precipitate was filtered out and recrystallized from Pr<sup>i</sup>OH.

***N*-(2-Chloro-5-nitrophenyl)propanamide (4a).** Yield 6.43 g (97%), mp 120-122 °C. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) δ: 1.11 t (3H, CH<sub>3</sub>, *J* = 7.5 Hz), 2.37 q (2H, CH<sub>2</sub>, *J* = 7.5 Hz), 7.78 d (1H, H<sup>3</sup>, *J* = 8.8 Hz), 7.98 dd (1H, H<sup>4</sup>, *J*<sub>1</sub> = 8.9 Hz, *J*<sub>2</sub> = 2.7 Hz), 8.75 d (1H, H<sup>6</sup>, *J* = 2.7 Hz), 9.75 (s, 1H, NH). ESI-HRMS: *m/z* calcd for C<sub>9</sub>H<sub>10</sub>ClN<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup> 229.6324, found 229.6327

***N*-(4-Chloro-3-nitrophenyl)propanamide (4b).** Yield 6.5 g (98%), mp 97-100 °C. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) δ: 1.09 t (3H, CH<sub>3</sub>, *J* = 7.5 Hz), 2.37 q (2H, CH<sub>2</sub>, *J* = 7.5 Hz), 7.68 d (1H, H<sup>5</sup>, *J* = 8.9 Hz), 7.77 dd (1H, H<sup>6</sup>, *J*<sub>1</sub> = 8.9 Hz, *J*<sub>2</sub> = 2.5 Hz), 8.42 d (1H, H<sup>2</sup>, *J* = 2.5 Hz), 10.40 s (1H, NH). ESI-HRMS: *m/z* calcd for C<sub>9</sub>H<sub>10</sub>ClN<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup> 229.6324, found 229.6329

**Method for the synthesis of *N*-[2-(1*H*-benzimidazol-1-yl)-5-nitrophenyl]propanamide (5a) and *N*-[4-(1*H*-benzimidazol-1-yl)-3-nitrophenyl]propanamide (5b).** Amide **4a** or **4b** (6 g, 26.2 mmol), K<sub>2</sub>CO<sub>3</sub> (5.43 g, 39.4 mmol) and benzimidazole (3.25 g, 27.5 mmol) was heated for 8.5 h in DMF (70 ml) at 120 °C. After cooling, the reaction mixture was poured into water. The precipitate was filtered off and recrystallized from Pr<sup>i</sup>OH.

***N*-[2-(1*H*-Benzimidazol-1-yl)-5-nitrophenyl]propanamide (5a).** Yield 4.63 g (57%), mp 222-226 °C. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) δ: 0.88 t (3H, CH<sub>3</sub>, *J* = 7.5 Hz), 2.09 q (2H, CH<sub>2</sub>, *J* = 7.5 Hz), 7.13 m (1H, H<sup>7</sup>), 7.30 m (2H, H<sup>4',5'</sup>), 7.80 dd (2H<sup>3',6'</sup>, *J*<sub>1</sub> = 9.0 Hz, *J*<sub>2</sub> = 2.4 Hz), 8.18 dd (1H, H<sup>6</sup>, *J*<sub>1</sub> = 8.8, *J*<sub>2</sub> = 2.5 Hz), 8.46 (s, 1H, H<sup>2'</sup>), 8.76 d (1H, H<sup>2</sup>, *J* = 2.5 Hz), 9.79 s (1H, NH). <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz) δ: 9.98, 29.47, 111.41, 120.59, 120.76, 121.28, 123.24, 124.17, 129.41, 133.64, 134.21, 134.89, 144.22, 144.47, 147.91, 173.29. ESI-HRMS: *m/z* calcd for C<sub>16</sub>H<sub>15</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> 311.3074, found 311.3071

***N*-[4-(1*H*-Benzimidazol-1-yl)-3-nitrophenyl]propanamide (5b).** Yield 5.12 g (63%), mp 187-191 °C. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) δ: 1.13 t (3H, CH<sub>3</sub>, *J* = 7.5 Hz), 2.43 q (2H, CH<sub>2</sub>, *J* = 7.5 Hz), 7.20 m (1H, H<sup>5'</sup>), 7.25-7.32 m (2H, H<sup>4',6'</sup>), 7.77 dd (2H, H<sup>5',7'</sup>, *J*<sub>1</sub> = 8.9 Hz, *J*<sub>2</sub> = 1.4 Hz), 8.03 dd (1H, H<sup>6</sup>, *J*<sub>1</sub> = 8.7 Hz, *J*<sub>2</sub> = 2.4 Hz), 8.43 s (1H, H<sup>2'</sup>), 8.66 d (1H, H<sup>2</sup>, *J* = 2.4 Hz), 10.60 (s, 1H, NH). <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz) δ: 9.96, 30.22, 110.48, 115.86, 120.51, 123.19, 123.91, 124.54, 124.79, 131.52, 135.27, 141.46, 143.69, 144.72, 145.77, 173.76. ESI-HRMS: *m/z* calcd for C<sub>16</sub>H<sub>15</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> 311.3074, found 311.3076

**Method for the synthesis of 2-(1*H*-benzimidazol-1-yl)-5-nitroaniline (1a) and 4-(1*H*-benzimidazol-1-yl)-3-nitroaniline (1b).** Amide **5a** or **5b** (4 g, 12.9 mmol) was heated for 1.5 h in 50% H<sub>2</sub>SO<sub>4</sub> (50 ml) at 40 °C. The reaction mass was poured into ice and treated with NH<sub>4</sub>OH to pH = 7-8. The precipitate was filtered off and recrystallized from CHCl<sub>3</sub>.

**2-(1*H*-Benzimidazol-1-yl)-5-nitroaniline (1a).** Yield 3.02 g (92%), mp 231-236 °C. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) δ: 5.76 s (2H, NH<sub>2</sub>), 7.20 m (1H, H<sup>6'</sup>), 7.29 m (2H, H<sup>4',5'</sup>), 7.41 d (1H, H<sup>3</sup>, *J* = 8.6 Hz), 7.48 dd (1H, H<sup>4</sup>, *J*<sub>1</sub> = 8.7 Hz, *J*<sub>2</sub> = 2.5 Hz), 7.79 m (2H, H<sup>6,7'</sup>), 8.34 d (1H, H<sup>2'</sup>, *J* = 2.1 Hz). <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz) δ: 110.7, 110.9, 111.6, 120.5, 122.9, 123.9, 125.8, 129.9, 134.2, 144.1, 144.3, 146.3, 148.9. ESI-HRMS: *m/z* calcd for C<sub>13</sub>H<sub>11</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup> 255.2441, found 255.2438

**4-(1*H*-Benzimidazol-1-yl)-3-nitroaniline (1b).** Yield 3.09 g (94%), mp 159-163 °C. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) δ: 6.21 s (2H, NH<sub>2</sub>), 7.02 dd (1H, H<sup>6</sup>, *J*<sub>1</sub> = 8.6, *J*<sub>2</sub> = 2.6 Hz), 7.09-7.16 m (1H, H<sup>6'</sup>), 7.26 m (2H, H<sup>4',5'</sup>), 7.33-7.42 m (2H, H<sup>2,5</sup>), 7.67-7.79 m (1H, H<sup>7'</sup>), 8.30 d (1H, H<sup>2'</sup>, *J* = 1.5 Hz). <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz) δ: 109.3, 110.5, 115.9, 118.9, 120.4, 122.8, 124.0, 131.7, 135.7, 143.6, 145.1, 146.9, 151.4. ESI-HRMS: *m/z* calcd for C<sub>13</sub>H<sub>11</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup> 255.2441, found 255.2439

**Method for the synthesis of 1-(2,4-dinitrophenyl)-1*H*-benzimidazole (7).** 2,4-Dinitrochlorobenzene **6** (10 g, 49.4 mmol), K<sub>2</sub>CO<sub>3</sub> (10.22 g, 74.0 mmol) and benzimidazole (5.83 g, 49.4 mmol) were heated for 1 h in DMF (100 ml) at 100 °C. After cooling, the reaction mixture was poured into water. The precipitate was filtered off and recrystallized from Pr<sup>i</sup>OH. Yield 13.6 g (97%), mp 171-174 °C. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) δ: 7.38 – 7.30 m (3H, H<sup>5,6,7'</sup>), 7.82 m (1H, H<sup>4</sup>), 8.21 d (1H, H<sup>6'</sup>, *J* = 8.7 Hz), 8.57 s (1H, H<sup>2</sup>), 8.78 dd (1H, H<sup>5'</sup>, *J*<sub>1</sub> = 8.7 Hz, *J*<sub>2</sub> = 2.6 Hz), 9.05 d (1H, H<sup>3'</sup>, *J* = 2.6 Hz). <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz) δ: 110.5, 120.9, 122.5, 123.9, 124.8, 130.0, 132.1, 134.2, 134.5, 143.9, 144.1, 145.2, 147.6. ESI-HRMS: *m/z* calcd for C<sub>13</sub>H<sub>9</sub>N<sub>4</sub>O<sub>4</sub> [M+H]<sup>+</sup> 285.2270, found 285.2267

**Method for the synthesis of 2-(1*H*-benzimidazol-1-yl)-*N*-hydroxy-5-nitroaniline (8).**

A solution of SnCl<sub>2</sub>·H<sub>2</sub>O (2.4 g, 10.5 mmol) in HCl (4% aq., 100 ml) was added to the solution of dinitro compound **7** (1 g, 3.5 mmol) in Pr<sup>i</sup>OH (50 ml) at 50 °C. After 20 min, the reaction mixture was cooled and neutralized with NH<sub>4</sub>OH to pH 7-8 and extracted with several portions of hot chloroform (Σ = 80 ml). After distilling about 70 ml of chloroform, compound **8** was obtained. Yield 0.83 g (88 %), mp 193-197 °C. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) δ: 7.22-7.31 m (3H, H<sup>5',6',7'</sup>), 7.56 d (1H, H<sup>3</sup>, *J* = 8.5 Hz), 7.73-7.79 m (2H, H<sup>4,4'</sup>), 8.06 d (1H, H<sup>6</sup>, *J* = 2.6 Hz), 8.36 s (1H, H<sup>2</sup>), 8.83 s (1H, NH), 8.97 s (1H, OH). <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz) δ: 108.7,


111.9, 114.4, 120.5, 123.0, 123.8, 126.3, 129.1, 134.1, 144.1, 144.2, 148.8, 148.9. ESI-HRMS:  $m/z$  calcd for  $C_{13}H_{11}N_4O_3$   $[M+H]^+$  271.2435, found 271.2431

**Method for the synthesis of 4-(1*H*-benzimidazol-1-yl)benzene-1,3-diamine (9).** Titanium trichloride (15% solution in 10% HCl, 7 g, 40 ml, 45.6 mmol) was added to a solution of dinitro compound **7** (1 g, 3.5 mmol) in 36% HCl (50 ml) at 50 °C. After 10 min, the mixture was cooled and neutralized with  $NH_4OH$  to pH 7-8 and extracted with several portions of hot chloroform ( $\Sigma$  = 80 ml). After distillation of chloroform, compound **9** was obtained. The product was purified by recrystallization in a mixture of hexane -  $Pr^iOH$ . Yield 0.74 g (94%), mp 115-118 °C.  $^1H$  NMR (DMSO- $d_6$ , 500 MHz)  $\delta$ : 3.51 s (2H,  $NH_2$ ), 3.66 s (2H,  $NH_2$ ), 6.09-6.19 m (2H,  $H^{2,6}$ ), 6.91 d (1H,  $H^5$ ,  $J$  = 8.6 Hz), 7.18-7.34 m (3H,  $H^{4',5',6'}$ ), 7.84 d (1H,  $H^{7'}$ ,  $J$  = 7.1 Hz), 7.92 (c, 1H,  $H^{2'}$ ).  $^{13}C$  NMR (DMSO- $d_6$ , 125 MHz)  $\delta$ : 101.9, 106.0, 111.0, 112.8, 120.6, 122.7, 123.6, 129.5, 134.8, 143.7, 144.0, 144.2, 148.6. ESI-HRMS:  $m/z$  calcd for  $C_{13}H_{13}N_4$   $[M+H]^+$  225.2612, found 225.2608


**Method for the synthesis of 2-(1*H*-benzimidazol-1-yl)-5-nitroaniline (1a) in the reaction of *orto*-reduction.** A solution of  $TiCl_3$  (3.3 g, 21.4 mmol) in HCl was added to a solution of dinitro compound **7** (1 g, 3.5 mmol) in 36% HCl (50 ml) at 30 °C for 5 min, which was prepared by mixing 15%  $TiCl_3$  solution in 10% HCl (18.5 ml) and 36% HCl (31.5 ml). The reaction mixture was cooled and neutralized with  $NH_4OH$  to pH 7-8 and extracted with several portions of hot chloroform ( $\Sigma$  = 80 ml). After distilling 70 ml of chloroform, compound **1a** was obtained. Yield 0.83g (93 %).

**Method for the synthesis of 2-(5-nitro-1*H*-benzimidazol-1-yl)aniline (2).** A solution of  $TiCl_3$  (3.3 g, 21.4 mmol) in HCl was added to a solution of dinitro compound **7** (1 g, 3.5 mmol) in 36% HCl (50 ml) at 30 °C for 5 min, which was prepared by mixing 15%  $TiCl_3$  solution in 10% HCl (18.5 ml) and 36% HCl (31.5 ml). Then 70% aqueous  $PrOH$  (100 ml) was introduced, and this was stirred at 80 °C for 4 h. After cooling, the mixture was neutralized with  $NH_4OH$  to pH 7-8 and extracted with several portions of hot chloroform ( $\Sigma$  = 80 ml). After distillation of chloroform, compound **2** was obtained. The product was purified by recrystallization in a mixture of  $CHCl_3$  -  $Pr^iOH$ . Yield 0.76 g (86%), mp 203-205°C.  $^1H$  NMR (DMSO- $d_6$ , 500 MHz)  $\delta$ : 5.22 s (2H,  $NH_2$ ), 6.71 t (1H,  $H^4$ ,  $J$  = 8.8 Hz), 6.94 dd (1H,  $H^6$ ,  $J_1$  = 8.6,  $J_2$  = 1.8 Hz) 7.17 dd (1H,  $H^3$ ,  $J_1$  = 8.4,  $J_2$  = 2.0 Hz), 7.27 t (1H,  $H^5$ ,  $J$  = 8.9 Hz), 7.32 d (1H,  $H^{7'}$ ,  $J$  = 8.6 Hz), 8.17 dd (1H,  $H^{6'}$ ,  $J_1$  = 8.7 Hz,  $J_2$  = 2.2 Hz), 8.61 s (1H,  $H^{2'}$ ), 8.63 d (1H,  $H^{4'}$ ,  $J$  = 2.2 Hz).  $^{13}C$  NMR (DMSO- $d_6$ , 125 MHz)  $\delta$ : 112.3, 116.4, 116.7, 116.9, 119.3, 119.8, 128.7, 131.1, 139.3, 143.4, 143.7, 145.4, 149.3. ESI-HRMS:  $m/z$  calcd for  $C_{13}H_{11}N_4O_2$   $[M+H]^+$  255.2441, found 255.2437


## 2. NMR Spectral Data




<sup>1</sup>H NMR spectrum of *N*-(2-chloro-5-nitrophenyl)propanamide (**4a**) (DMSO-*d*<sub>6</sub>)




<sup>1</sup>H NMR spectrum of *N*-(4-chloro-3-nitrophenyl)propanamide (**4b**) (DMSO-*d*<sub>6</sub>)





<sup>1</sup>H NMR spectrum of *N*-[2-(1*H*-benzimidazol-1-yl)-5-nitrophenyl]propanamide (**5a**) (DMSO-*d*<sub>6</sub>)




<sup>13</sup>C NMR spectrum of *N*-[2-(1*H*-benzimidazol-1-yl)-5-nitrophenyl]propanamide (**5a**) (DMSO-*d*<sub>6</sub>)



Fragment of  $^1\text{H}$ - $^1\text{H}$  NOESY spectrum of *N*-[2-(1*H*-benzimidazol-1-yl)-5-nitrophenyl]propanamide (**5a**) (DMSO- $d_6$ )




<sup>1</sup>H NMR spectrum of *N*-[4-(1*H*-benzimidazol-1-yl)-3-nitrophenyl]propanamide (**5b**) (DMSO-*d*<sub>6</sub>)





<sup>13</sup>C NMR spectrum of *N*-[4-(1*H*-benzimidazol-1-yl)-3-nitrophenyl]propanamide (**5b**) (DMSO-*d*<sub>6</sub>)







$^1\text{H}$ - $^1\text{H}$  NOESY spectrum of *N*-[4-(1*H*-benzimidazol-1-yl)-3-nitrophenyl]propanamide (**5b**) ( $\text{DMSO-}d_6$ )





$^1\text{H}$  NMR spectrum of 2-(1*H*-benzimidazol-1-yl)-5-nitroaniline (**1a**) (DMSO- $d_6$ )




$^{13}\text{C}$  NMR spectrum of 2-(1*H*-benzimidazol-1-yl)-5-nitroaniline (**1a**) (DMSO- $d_6$ )




Fragment of  $^1\text{H}$ - $^1\text{H}$  NOESY spectrum of 2-(1*H*-benzimidazol-1-yl)-5-nitroaniline (**1a**) ( $\text{DMSO-}d_6$ )





$^1\text{H}$  NMR spectrum of 4-(1*H*-benzimidazol-1-yl)-3-nitroaniline (**1b**) (DMSO- $d_6$ )




$^{13}\text{C}$  NMR spectrum of 4-(1*H*-benzimidazol-1-yl)-3-nitroaniline (**1b**) (DMSO- $d_6$ )




Fragment of  $^1\text{H}$ - $^1\text{H}$  NOESY spectrum of 4-(1*H*-benzimidazol-1-yl)-3-nitroaniline (**1b**) ( $\text{DMSO-}d_6$ )




<sup>1</sup>H NMR spectrum of 1-(2,4-dinitrophenyl)-1*H*-benzimidazole (**7**) (DMSO-*d*<sub>6</sub>)




<sup>13</sup>C NMR spectrum of 1-(2,4-dinitrophenyl)-1*H*-benzimidazole (**7**) (DMSO-*d*<sub>6</sub>)



<sup>1</sup>H NMR spectrum of 2-(1H-benzimidazol-1-yl)-N-hydroxy-5-nitroaniline (**8**) (DMSO-*d*<sub>6</sub>)





<sup>13</sup>C NMR spectrum of 2-(1H-benzimidazol-1-yl)-N-hydroxy-5-nitroaniline (**8**) (DMSO-*d*<sub>6</sub>)




Fragment of  $^1\text{H}$ - $^1\text{H}$  NOESY spectrum of 2-(1*H*-benzimidazol-1-yl)-*N*-hydroxy-5-nitroaniline (**8**) (DMSO- $d_6$ )








<sup>1</sup>H NMR spectrum of 4-(1*H*-benzimidazol-1-yl)benzene-1,3-diamine (**9**) (DMSO-*d*<sub>6</sub>)




<sup>13</sup>C NMR spectrum of 4-(1*H*-benzimidazol-1-yl)benzene-1,3-diamine (**9**) (DMSO-*d*<sub>6</sub>)



<sup>1</sup>H NMR spectrum of 2-(5-nitro-1*H*-benzimidazol-1-yl)aniline (**2**) (DMSO-*d*<sub>6</sub>)



<sup>13</sup>C NMR spectrum of 2-(5-nitro-1*H*-benzimidazol-1-yl)aniline (**2**) (DMSO-*d*<sub>6</sub>)



Fragment of  $^1\text{H}$ - $^1\text{H}$  NOESY spectrum of 2-(5-nitro-1*H*-benzimidazol-1-yl)aniline (**2**) ( $\text{DMSO-}d_6$ )